Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.37 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232719 | 0.84 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL728884 | 0.82 | ADORA3 (0.42) | KDM4EL3MBTL1ATMUSP2CASP1 | |
| SCHEMBL728712 | 0.78 | KDM4E (0.36) | KDM4EL3MBTL1ATMUSP2CASP1 | |
| SCHEMBL728873 | 0.75 | HPGD (0.44) | KDM4EL3MBTL1KMT2AMAPK1MAPT | |
| SCHEMBL730647 | 0.75 | MAPT (0.42) | KDM4EL3MBTL1USP2CASP1CASP7 | |
| SCHEMBL1233300 | 0.74 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL1894211 | 0.74 | TLR7 (0.41) | KDM4EUSP2CASP1CASP7MEN1 | |
| SCHEMBL5963494 | 0.72 | TLR7 (0.45) | TLR7TLR8 | |
| SCHEMBL1233949 | 0.72 | TLR7 (0.43) | TLR7TLR8 | |
| SCHEMBL5569543 | 0.71 | TLR7 (0.44) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-05-17 | — | — | US | disclosed |
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-7879849-B2 | such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-7544697-B2 | Pyrazolopyridines and analogs thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1863809-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863813-A2 | PYRAZOLO[3,4-C]QUINOLINES, PYRAZOLO[3,4-C]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107771-A2 | PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107753-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | IL4, IL2, IL5 | KDM4E 3301/4885L3MBTL1 4598/4885ATM 3100/4885 |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | KDM4E 1465/4885L3MBTL1 3975/4885ATM 1256/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | KDM4E 1735/4885L3MBTL1 4466/4885ATM 745/4885 |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL4I1, IL2 | KDM4E 1465/4885L3MBTL1 3975/4885ATM 1256/4885 |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL2, IL4I1 | KDM4E 1735/4885L3MBTL1 4466/4885ATM 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.